TY - JOUR
T1 - Liposomal alendronate for the treatment of restenosis
AU - Gutman, Dikla
AU - Golomb, Gershon
PY - 2012/7/20
Y1 - 2012/7/20
N2 - The current treatment for coronary restenosis following balloon angioplasty involves the use of a mechanical or drug eluting stent (DES). The advent of DES systems has effectively allayed much of the challenge of restenosis that has plagued the success of percutaneous coronary interventions (PCI). However, there are certain limitations to DES use, among which is late stent thrombosis. Innate immunity and inflammation are of major importance in the overreaction of the wound healing response to PCI-induced vascular injury, which leads to restenosis. Liposomes containing alendronate have been shown to deplete circulating monocytes and reduce experimental restenosis. This review presents a unique systemic approach for treating restenosis with alendronate liposomal nano-carriers and reports on its formulation development, formulation variables affecting monocyte/macrophage targeting, pharmacokinetics (PK) and biodistribution, in vitro and in vivo anti-inflammatory effect, and the recent results of the phase II clinical trial.
AB - The current treatment for coronary restenosis following balloon angioplasty involves the use of a mechanical or drug eluting stent (DES). The advent of DES systems has effectively allayed much of the challenge of restenosis that has plagued the success of percutaneous coronary interventions (PCI). However, there are certain limitations to DES use, among which is late stent thrombosis. Innate immunity and inflammation are of major importance in the overreaction of the wound healing response to PCI-induced vascular injury, which leads to restenosis. Liposomes containing alendronate have been shown to deplete circulating monocytes and reduce experimental restenosis. This review presents a unique systemic approach for treating restenosis with alendronate liposomal nano-carriers and reports on its formulation development, formulation variables affecting monocyte/macrophage targeting, pharmacokinetics (PK) and biodistribution, in vitro and in vivo anti-inflammatory effect, and the recent results of the phase II clinical trial.
KW - Bisphosphonate
KW - Inflammation
KW - Liposome
KW - Monocytes/macrophages
KW - Restenosis
UR - http://www.scopus.com/inward/record.url?scp=84862688093&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2011.11.037
DO - 10.1016/j.jconrel.2011.11.037
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 22178594
AN - SCOPUS:84862688093
SN - 0168-3659
VL - 161
SP - 619
EP - 627
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 2
ER -